Oral and IV Baclofen in Adult Volunteers
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 5/5/2014 |
| Start Date: | January 2013 |
| End Date: | January 2014 |
Prevention of Baclofen Withdrawal Syndrome: Two-Way Crossover Study of Oral and Intravenous Baclofen in Healthy Adult Volunteers
The primary objective of this study is to characterize baclofen pharmacokinetics following
oral and intravenous administration in patients who are on chronic oral baclofen therapy.
The secondary objective is to determine the safety profile of an IV baclofen formulation.
This study is a randomized crossover study with two treatment arms. All subjects will
receive a dose of oral baclofen and a dose of IV baclofen on separate study days. Whether
the oral or intravenous form is given on the first study day will be randomized in a 1:1
manner.
The pharmacokinetic and tolerability information gained from this study will support the
development of further studies to assess the use of IV baclofen to prevent or treat baclofen
withdrawal syndrome.
oral and intravenous administration in patients who are on chronic oral baclofen therapy.
The secondary objective is to determine the safety profile of an IV baclofen formulation.
This study is a randomized crossover study with two treatment arms. All subjects will
receive a dose of oral baclofen and a dose of IV baclofen on separate study days. Whether
the oral or intravenous form is given on the first study day will be randomized in a 1:1
manner.
The pharmacokinetic and tolerability information gained from this study will support the
development of further studies to assess the use of IV baclofen to prevent or treat baclofen
withdrawal syndrome.
Inclusion Criteria:
Subjects will be eligible to participate in the study if all of the following conditions
exist:
1. Males and females between the ages of 18-65.
2. Subjects are capable of giving informed consent.
3. Female subjects must be post-menopausal for at least 1 year, or surgically incapable
of bearing children, or practicing at least one or more of the following methods of
contraception for three months prior to, and during the study: hormonal, intrauterine
device (IUD), or barrier method in combination with a spermicide.
4. Subject should be medication free, other than study drug, for 48 hours before through
24 hours after study drug administration. If the need for medication is identified
during this time period, it will be discussed with and approved by the PI.
-
Exclusion Criteria:
Subjects will be excluded from participation in the study if any of the following
conditions exist:
1. Women who are pregnant.
2. Women who are breast feeding.
3. Subject has a history of intolerance to IV administration of medication.
4. Subject has a known hypersensitivity to baclofen.
5. Subject has a significant history of cardiac, neurologic, psychiatric, oncologic,
endocrine, metabolic, renal or hepatic disease
6. Subject has taken or used any investigational drug or device in the 30 days prior to
screening.
7. Subject has taken either prescribed or over the counter medication for 48 hours prior
to baclofen administration on either of the study days.
8. Subject reveals clinically significant abnormalities on screening laboratory tests.
9. Subject is a non-English speaker, such that ability to ascertain neurological status
would require an interpreter.
We found this trial at
1
site
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
Click here to add this to my saved trials
